Breast Cancer IndexSM
BCI Indications for Use and Limitations
BCI provides a quantitative assessment of the likelihood of distant recurrence in patients diagnosed with ER+ node-negative breast cancer, and prediction of likelihood of benefit from extended (>5 year) endocrine therapy in patients who are recurrence-free after an initial 5 years of adjuvant endocrine therapy. Treatment decisions require correlation with all other clinical findings. This test was developed and its performance characteristics determined by bioTheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. bioTheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high complexity clinical laboratory testing.
1. Zhang et al, Clin Cancer Res. 2013;19:4196-205. 2. Sgroi et al, Lancet Oncology. 2013;14:1067-76. 3. Sgroi et al, J Natl Cancer Inst. 2013;105:1036-1042.